Solving the Conglomerate Discount with Momentum; Initiating OUTPERFORM, PT $94

Research evidence excerpt

Solving the Conglomerate Discount with Momentum; Initiating OUTPERFORM, PT $94

Situation Overview

We believe that Solventum's spin-off from 3M, which has attracted the attention of activist

investor Trian Fund Management, represents a special situation that is primed with potential

financial engineering catalysts to unlock value along with the company’s long-term margin

improvement plan that is still in its early innings and should lead to further returns of capital. In

our view, Trian's approximately 5% beneficial ownership stake in Solventum along with the

company’s stated margin improvement plan represents significant and underappreciated catalysts

for value realization. Trian has published two open letters (Jan’25 and Apr’26) that systematically

build the case for operational improvement, portfolio simplification, and more aggressive capital

return. The core of Trian's thesis is that Solventum operates as a mini-conglomerate housing

operationally distinct businesses under one corporate umbrella, suppressing both execution and

valuation, which we agree with as well.

Trian has specifically identified the HIS and DS segments as non-core to the MS franchise, arguing

that HIS shares no common technology platform, customer base, sales force, or distribution

channel with the core wound care and surgical businesses, while DS addresses an entirely

different clinical workflow with a separate regulatory environment and competitive set. Trian has

observed that Solventum trades at a discount to each of its subsidiary peer groups and even trades

below its former parent, 3M, despite historically being 3M's best-performing division. Prior to the

spin-off, sell-side analysts had estimated a standalone valuation of approximately $33 billion (per